durham-north-carolina
(3)
Michael Polk
Michael Polk is the President and CEO of Implus, the Durham, North Carolina maker of footcare, fitness and sporting goods brands like Sof Sole, Spenco, Yaktrax and TriggerPoint. A first-generation American and career consumer-goods operator, he spent decades climbing through Procter & Gamble, Kraft Foods and Unilever before running Newell Brands for eight years, where he led a transformation that roughly tripled enterprise value. Since 2020 he has paired the Implus job with an advisory role at private equity firm Berkshire Partners, trading the glare of a public-company quarter for the hands-on work of building brands shoulder-to-shoulder with a smaller team.
Jennifer Aspell
Jennifer Aspell is the CEO of BrightView Technologies, a Durham, North Carolina optics company that engineers micro lens array films to shape and manage light for displays, AR/VR, automotive, LiDAR, sensing and LED lighting. An electrical engineer trained at Rensselaer, UC Berkeley and Purdue, she started out at Bell Laboratories building technology for long-haul optical networks before moving through Lucent, JDS Uniphase and Tyco Electronics. She took the helm of BrightView in 2010 after the recession gutted its original rear-projection-TV market, and rebuilt it into a global supplier serving more than 200 customers, capped by a $7M Series B in 2025 led by Forvia Hella and Technology Venture Partners.
Michael Milburn
Michael V. Milburn is the CEO and President of GeneCentric Therapeutics, a Durham, North Carolina biotech building RNA-based liquid biopsy tools that read a tumor's behavior from a single tube of blood. A structural biologist by training, he helped solve the first crystal structures of the Ras cancer protein at Berkeley in the late 1980s, then spent decades building research engines at Sirtris, Plexxikon, and Metabolon before taking the top job at GeneCentric in 2019. His current bet: that the fragments of DNA shed by tumors carry enough information to infer gene expression, not just mutations, turning a blood draw into a near-complete molecular portrait of cancer.